Also fairly interesting in the study was the fact that there are more drugs in research across all active research phases in 2014. One very intersting statistic from this chart is the large increase in number of launched drugs. Lloyd credits this increase in to Pharma companies looking to a drug post approval and continuing to develop and increase the value of each drug in their pipeline.
What else does the Citeline Pharma R&D Annual Review 2014 contain insight on?
- -The trends in growth across Phase I, II and III over the years
- -The companies who have the most drugs in thier pipeline and origionated drugs
- -Distribution of pharma countries across geographic regions
- -The therapeutic areas Pharma companies are looking towards in their pipeline
- And more!
Download the full 2013 Clinical Trials Scoreboard report at Citeline.
Does the amount of organic growth that happened over the past year surprise you?